Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sandrine Niyongere"'
Autor:
Fahad Alkaabba, Matthew Williams, Elizabeth Corley, Hanan Alharthy, Kathryn A.F. Kline, Seung Tae Lee, Michael Kallen, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Moaath K. Mustafa Ali
Publikováno v:
Blood. 140:3237-3238
Autor:
Hanan Alharthy, Fahad Alkaabba, Matthew Williams, Elizabeth Corley, Kathryn A.F. Kline, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Moaath K. Mustafa Ali
Publikováno v:
Blood. 140:9025-9026
Autor:
Dominique R Bollino, Yuchen Liu, Osman Mohamed Bah, Katherine Caprinolo, Jinoos Zarrabi, Sunita Philip, Ezzat Mostafa, Rena G. Lapidus, Zeba Singh, Michael Kallen, Yi Ning, Rima Koka, Maria R. Baer, Sandrine Niyongere, Vu H. Duong, Erin T Strovel, Molly Graveno, Ashkan Emadi
Publikováno v:
Blood. 140:9044-9045
Autor:
Elizabeth M. Corley, Moaath Mustafa Ali, Ashkan Emadi, Kathryn V. Kline, Danielle Sewell, Vu H. Duong, Sandrine Niyongere, Jennie Y. Law, Maria R. Baer, Seung Tae Lee, Hanan Alharthy
Publikováno v:
Blood. 138:4454-4454
Introduction Mutations have become essential in determining risk stratification for acute myeloid leukemia (AML) and are often used to guide treatment. Variants of unknown significance (VUS) can be classified as pathogenic or benign once their roles
Autor:
Dominique R Bollino, Rena G. Lapidus, Maria R. Baer, Veronica Kflu, Jinoos Zarrabi, Osman Mohamed Bah, Sunita Philip, Sandrine Niyongere, Erin T. Strovel, Ashkan Emadi, Vu H. Duong
Publikováno v:
Blood. 138:4433-4433
Background: Despite new therapeutic advances, acute myeloid leukemia (AML) still has poor outcomes, especially in patients with relapsed or refractory (R/R) disease with complex karyotype (CK) and/or TP53 mutation. Venetoclax (Ven), an oral BCL-2 inh
Autor:
Max An, Justin Lawson, James Childress, Jack Masur, Brian Barr, Maria R. Baer, Jasmin Sahbaz, Sandrine Niyongere, Vu H. Duong, Tahreem Iqbal, Safwan Muhammad, Gabriela Sanchez-Petitto, Jennie Y. Law, Olga Goloubeva, Ashkan Emadi
Publikováno v:
Blood. 136:37-38
Background: The incidence of both myeloid malignancies and cardiovascular disease (CVD) increases with age, and cardiac disease is the most frequent cause of non-hematologic morbidity in patients with myelodysplastic syndrome (MDS). We aimed to study
Autor:
Wendy Walinski, Sandrine Niyongere, Amanda Przespolewski, Stephanie Halliwell, Kristopher Attwood, Elizabeth A. Griffiths, James E. Thompson, Ashkan Emadi, Vu H. Duong, Kemji Eke, Amro Elshoury, Maria R. Baer, Eunice S. Wang, Meriem Said
Publikováno v:
Blood. 136:20-21
Background: Poly (ADP-ribose) polymerase (PARP) enzymes are involved in repair of single-strand DNA breaks through base excision repair pathways. Inhibitors of PARP are approved for the treatment of BRCA1/2-mutant malignancies where they result in co
Autor:
Vu Doung, Ashkan Emadi, Maria R. Baer, Sandrine Niyongere, Emily J. Vannorsdall, Zeba N. Singh, Yamini Kathari
Publikováno v:
Blood. 136:6-7
Background: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with features of both myeloproliferative neoplasm and myelodysplastic syndrome (MDS). CMML is characterized by persistent blood monocytosis >1 x 109/L, bo
Autor:
Kira Feldman, Benjamin H. Durham, Elliot Stieglitz, Maria E. Balasis, Yan Ma, Christopher Letson, Markus Ball, Michael F. Berger, Justin Taylor, Alan F. List, YuLong Zhao, Mignon L. Loh, Alexis Vedder, Salma Youssef, Young Rock Chung, Omar Abdel-Wahab, Virginia M. Klimek, Xiao Jing Zhang, Akihide Yoshimi, Wendy Yang, Sandrine Niyongere, Sydney X. Lu, Eric Padron, Hailing Zhang, Qing Zhang, Stanley Chun-Wei Lee
Publikováno v:
Blood. 130:397-407
Chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap disorders characterized by monocytosis, myelodysplasia, and a characteristic hypersensitiv
Autor:
Sandrine Niyongere, Shivani Kapoor, Jonelle K. Lee, Danilo Perrotti, Mario Scarpa, Prerna Singh, Maria R. Baer, Goutham Narla
Publikováno v:
Blood. 134:1276-1276
Introduction fms-like tyrosine like kinase 3 internal tandem duplication (FLT3-ITD), present in acute myeloid leukemia (AML) cells of 30% of patients, results in constitutive and aberrant FLT3 signaling and, clinically, short disease-free survival. E